Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size By Type (1g/20ml, 1.25g/25ml), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market was valued at USD 4.1 billion in 2023 and is projected to reach USD 6.3 billion by 2031, growing at a CAGR of 5.6% during the forecast period from 2023 to 2031. The market growth is primarily driven by the increased utilization of immunoglobulin therapies to combat the immune complications associated with COVID-19 and its variants. As healthcare systems globally shift toward improved immunotherapy and antibody-based treatments, the demand for intravenous human immunoglobulin (IVIG), particularly the pH4-stabilized formulation, continues to rise.

Drivers:

1. Rising Incidence of Immune Dysregulation due to COVID-19:

COVID-19 has shown significant immunological impacts, including cytokine storms and post-viral complications, which require immunoglobulin therapy. IVIG (pH4) is widely used in managing such cases, boosting its global demand.

2. Increasing Clinical Trials and Regulatory Approvals:

Numerous ongoing trials are investigating IVIG for various post-COVID conditions, including MIS-C (Multisystem Inflammatory Syndrome in Children), and long COVID. Positive trial outcomes and regulatory endorsements are fueling market expansion.

3. Expanding Applications Beyond COVID-19:

While initially targeted for acute COVID-related interventions, IVIG (pH4) is gaining usage in treating autoimmune disorders, neurological diseases, and inflammatory conditions, further widening its therapeutic scope.

Restraints:

1. High Cost and Limited Production Capacity:

Human IVIG is derived from pooled plasma, requiring complex manufacturing and rigorous quality control. Limited plasma donation rates and the high cost of production restrict scalability and affordability in low-income countries.

2. Risk of Adverse Effects and Infusion Reactions:

Though generally safe, IVIG (pH4) can cause adverse effects such as thromboembolic events and renal dysfunction, especially in critically ill patients. These risks necessitate careful patient monitoring and limit usage in some cases.

Opportunity:

1. Expansion in Emerging Markets and Biopharma Collaborations:

As healthcare access improves in Asia-Pacific, Latin America, and the Middle East, and with increased collaboration between plasma fractionation firms and local biopharma companies, the IVIG (pH4) market is poised for regional growth.

2. Innovations in Plasma Collection and Fractionation Technologies:

Advancements in recombinant plasma substitutes and enhanced purification techniques are reducing production time and improving yield, presenting new opportunities for market players to improve efficiency and availability.

Market by System Type Insights:

The Lyophilized (Freeze-Dried) Form segment dominated the market in 2023. Its benefits in terms of improved shelf-life, ease of transportation, and reduced need for cold chain logistics have made it the preferred formulation globally. However, the Liquid Form segment is gaining traction for its convenience in hospital settings, especially for acute treatments where immediate administration is necessary.

Market by End-use Insights:

Hospitals and Specialty Clinics represented the largest end-use segment in 2023, accounting for over 55% of the total market share. The centralized use of IVIG treatments in inpatient settings for critically ill COVID-19 patients, particularly during ICU admissions, underscores this dominance. Homecare settings are expected to see increased growth due to the shift toward chronic post-COVID treatment and immune support therapies.

Market by Regional Insights:

North America held the largest market share in 2023 due to a robust healthcare infrastructure, well-established plasma donation networks, and leading manufacturers based in the U.S. and Canada. Meanwhile, Asia-Pacific is anticipated to exhibit the fastest growth during the forecast period, driven by rising healthcare investments, improved diagnostic capabilities, and government initiatives supporting immunotherapy access.

Competitive Scenario:

Major players in the Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market include:

Grifols S.A.

CSL Behring

Takeda Pharmaceutical Company Limited

Octapharma AG

Kedrion Biopharma

Shanghai RAAS Blood Products Co., Ltd.

China Biologic Products Holdings, Inc.

These companies are focusing on increasing plasma collection capabilities, expanding global distribution networks, and developing next-generation IVIG formulations with enhanced safety and efficacy profiles.

Scope of Work – Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market

Key Market Developments:

2023: Takeda announced new Phase 3 trials evaluating IVIG (pH4) in pediatric COVID-19-related inflammatory conditions such as MIS-C.

2024: CSL Behring expanded its plasma collection centers across Asia-Pacific to meet the growing demand for IVIG therapies.

2025: Grifols introduced a new lyophilized formulation with extended shelf-life, optimized for pandemic preparedness programs.

FAQs:

1) What is the current market size of the Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market?

The market was valued at USD 4.1 billion in 2023.

2) What is the major growth driver of the Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market?

The primary growth driver is the rising use of IVIG therapies in managing COVID-19-related immune complications and broader immunological disorders.

3) Which is the largest region during the forecast period in the Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market?

North America is the largest region due to its advanced healthcare infrastructure and high adoption rate.

4) Which segment accounted for the largest market share in Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market?

The Hospitals and Specialty Clinics segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market?

Key players include Grifols S.A., CSL Behring, Takeda, Octapharma, Kedrion Biopharma, and Shanghai RAAS.